poisar

Stocks · News reference

8-K filing — SELLAS Life Sciences Group, Inc. (SLS)

SEC EDGARSEC EDGAR

Filed: 2026-11-17 AccNo: 0001104659-26-128825 Size: 227 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
edgar
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncSellas Life Sciences Group, Inc.

    SELLAS anuncia resultados positivos del ensayo pivotal de fase 3 REGAL, que demuestran que la vacuna inmunoterapéutica contra el cáncer galinpepimut-S (GPS) produjo una mejora estadísticamente significativa y clínicamente relevante de la supervivencia global en pacientes con leucemia mieloide aguda

    SELLAS Life Sciences announced positive results from its Phase 3 REGAL trial showing that galinpepimut-S (GPS), an immunotherapeutic cancer vaccine, demonstrated a statistically significant 41% reduction in risk of death in acute myeloid leukemia patients, with median overall survival of 24.0 months versus 14.7 months with standard treatment. The company plans to meet with the FDA and submit a biologics license application in the first half of 2027.

  2. Globenewswire IncSellas Life Sciences Group, Inc.

    SELLAS Life Sciences Divulga Dados Positivos do Estudo REGAL Pivotal de Fase 3, Indicando que Galinpepimut-S (GPS), a Vacina Imunoterapêutica Contra o Câncer, Demonstrou uma Melhora Estatisticamente Significativa e Clinicamente Relevante na Sobrevida Global de Pacientes com Leucemia Mieloide Aguda

    SELLAS Life Sciences announced positive Phase 3 REGAL trial results for its immunotherapeutic cancer vaccine Galinpepimut-S (GPS) in acute myeloid leukemia patients. GPS demonstrated a statistically significant 41% reduction in death risk with median overall survival of 24.0 months versus 14.7 months for best available treatment (p=0.035). The company plans to meet with the FDA and submit a Biologics License Application in the first half of 2027.

  3. Globenewswire IncSellas Life Sciences Group, Inc.

    SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid Leukemia

    SELLAS Life Sciences announced positive topline results from its Phase 3 REGAL trial of galinpepimut-S (GPS), an immunotherapeutic cancer vaccine for acute myeloid leukemia. GPS demonstrated a statistically significant 41% reduction in risk of death with median overall survival of 24.0 months versus 14.7 months for best available treatment (hazard ratio 0.59, p=0.035). The company plans to meet with the FDA and submit a Biologics License Application in the first half of 2027.